Global Albuterol Sulfate Inhalation Solution Market Size, Share and Trends Analysis Report, By Type (Albuterol Sulfate Inhalation Solution 0.083%, Albuterol Sulfate Inhalation Solution 0.042%, Albuterol Sulfate Inhalation Solution 0.021%, and Albuterol Sulfate Inhalation Solution 0.5%), By Application (Children and Adults), Forecast (2022-2028)

The global albuterol sulfate inhalation solution market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The global market is growing due to the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease. According to World Health Organization in May 2021, Asthma has affected 262 million people in 2019 and caused 461,000 deaths globally. Asthma almost affects almost 5%-10% of the global population that accounts for 23.4 million people including 7 million children. The demand for albuterol sulfate inhalation solution has increased substantially during the COVID-19 pandemic as doctors were prescribing this drug for the treatment of COVID-19 patients having breathing and respiratory problems. Additionally, the presence of key manufacturing companies and huge investment in research and development activities is boosting the growth of the global albuterol sulfate inhalation solution market in the forecast period.

For instance, In January 2022, US Food and Drug Administration approved new drug application named ANDA 214531 to The Ritedose Corp. for Albuterol Sulfate Inhalation Solution in 2 variants, 0.63 mg /3 mL and 1.25 mg/3 mL for the treatment of asthma in patients of 2 to 12 years of age.

Some major players in the market include Nephron Pharmaceuticals Corp., GlaxoSmithKline plc. , Teva Pharmaceutical Industries Ltd., Mylan N.V. among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc. , Teva Pharmaceutical Industries Ltd. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Albuterol Sulfate Inhalation Solution Market Report by Segment

By Type

• Albuterol Sulfate Inhalation Solution 0.083%
• Albuterol Sulfate Inhalation Solution 0.042%
• Albuterol Sulfate Inhalation Solution 0.021%
• Albuterol Sulfate Inhalation Solution 0.5%

By Application

• Children
• Adults

Global Albuterol Sulfate Inhalation Solution Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa